Infliximab for Treatment of Immune Adverse Events and Its Impact on Tumor Response.

Parvathareddy, Vishnupriyadevi; Selamet, Umut; Sen, Aditi A; Mamlouk, Omar; Song, Juhee; Page, Valda D; Abdelrahim, Maen; Diab, Adi; Abdel-Wahab, Noha; Abudayyeh, Ala

Parvathareddy, Vishnupriyadevi; Selamet, Umut; Sen, Aditi A; Mamlouk, Omar; Song, Juhee; Page, Valda D; Abdelrahim, Maen; Diab, Adi; Abdel-Wahab, Noha; Abudayyeh, Ala.

Afiliação

Parvathareddy V; Department of Nephrology, Baylor College of Medicine, Houston, TX 77030, USA.
Selamet U; Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Sen AA; Department of Nephrology, Baylor College of Medicine, Houston, TX 77030, USA.
Mamlouk O; Section of Nephrology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Unit 1468, 1400 Pressler Street, Houston, TX 77030, USA.
Song J; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Page VD; Section of Nephrology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Unit 1468, 1400 Pressler Street, Houston, TX 77030, USA.
Abdelrahim M; Institute of Academic Medicine and Weill Cornell Medical College, Houston Methodist Cancer Center, Houston, TX 77479, USA.
Diab A; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Abdel-Wahab N; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Abudayyeh A; Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.